Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amal Yussuf

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 19, 2023
Characterization of POT1 tumor predisposition syndrome: Tumor prevalence in a clinically diverse hereditary cancer cohortJennifer Herrera-Mullar, Kelly Fulk, Terra Brannan, et al.
Journal of Medical Genetics|August 3, 2023
<i>CHEK2</i> is not a Li-Fraumeni syndrome gene: time to update public resourcesCristina Fortuno, Marcy Richardson, Tina Pesaran, et al.
Familial Cancer|December 25, 2018
Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohortKelly Fulk, Holly LaDuca, Mary Helen Black, et al.
Human Mutation|January 4, 2020
Differences in patient ascertainment affect the use of gene-specified ACMG/AMP phenotype-related variant classification criteria: Evidence for TP53Cristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Cancer Genetics|September 23, 2020
Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testingCristina Fortuno, Tina Pesaran, Jessica Mester, et al.
Cancer Genetics|July 13, 2019
p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patientsCristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Cancer|December 7, 2021
Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristicsBrittany L Bychkovsky, Min-Tzu Lo, Amal Yussuf, et al.
Human Mutation|July 10, 2021
Case-case analysis addressing ascertainment bias for multigene panel testing implicates BRCA1 and PALB2 in endometrial cancerSharon E Johnatty, Tina Pesaran, Jill Dolinsky, et al.
Gynecologic Oncology|January 8, 2019
Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testingKelly Fulk, Michael R Milam, Shuwei Li, et al.
Human Mutation|July 17, 2021
An updated quantitative model to classify missense variants in the TP53 gene: A novel multifactorial strategyCristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 19, 2023
Characterization of POT1 tumor predisposition syndrome: Tumor prevalence in a clinically diverse hereditary cancer cohortJennifer Herrera-Mullar, Kelly Fulk, Terra Brannan, et al.
Journal of Medical Genetics|August 3, 2023
<i>CHEK2</i> is not a Li-Fraumeni syndrome gene: time to update public resourcesCristina Fortuno, Marcy Richardson, Tina Pesaran, et al.
Familial Cancer|December 25, 2018
Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohortKelly Fulk, Holly LaDuca, Mary Helen Black, et al.
Human Mutation|January 4, 2020
Differences in patient ascertainment affect the use of gene-specified ACMG/AMP phenotype-related variant classification criteria: Evidence for TP53Cristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Cancer Genetics|September 23, 2020
Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testingCristina Fortuno, Tina Pesaran, Jessica Mester, et al.
Cancer Genetics|July 13, 2019
p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patientsCristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Cancer|December 7, 2021
Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristicsBrittany L Bychkovsky, Min-Tzu Lo, Amal Yussuf, et al.
Human Mutation|July 10, 2021
Case-case analysis addressing ascertainment bias for multigene panel testing implicates BRCA1 and PALB2 in endometrial cancerSharon E Johnatty, Tina Pesaran, Jill Dolinsky, et al.
Gynecologic Oncology|January 8, 2019
Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testingKelly Fulk, Michael R Milam, Shuwei Li, et al.
Human Mutation|July 17, 2021
An updated quantitative model to classify missense variants in the TP53 gene: A novel multifactorial strategyCristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Pageof 4